Accueil / Tag Archives: Other Health

Tag Archives: Other Health

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

Friday, March 29th 2019 at 7:00pm UTC Data to be Presented at AACR Annual Meeting PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of …

Plus »

Definiens et Ultivue annoncent une collaboration visant à développer des offres conjointes dans le domaine de l’immunofluorescence multiplexe et de l’analyse d’image numérique par intelligence artificielle

Friday, March 29th 2019 at 6:03pm UTC CAMBRIDGE, Massachusetts–(BUSINESS WIRE)– Ultivue, un développeur de tests d’identification et de quantification des biomarqueurs tissulaires destinés aux laboratoires de recherche translationnelle et en pathologie, et Definiens, une société pionnière de l’analyse des images basée sur l’intelligence artificielle, ont annoncé aujourd’hui une collaboration visant …

Plus »

Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis

Friday, March 29th 2019 at 3:11pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer in artificial intelligence (AI) based image analysis, today announced a collaboration to expand Definiens standardized IO-Panel capabilities to IF. The …

Plus »

Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

Friday, March 29th 2019 at 10:30am UTC —PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of Pediatric Nephrology 50th Annual Meeting— —Company Announces Initiation of Participant Screening for PHYOX2 Pivotal Trial in PH1 and PH2— CAMBRIDGE, Mass.–(BUSINESS WIRE)– Dicerna™ …

Plus »

CORRECTING and REPLACING OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy

Thursday, March 28th 2019 at 10:48pm UTC LATHAM, N.Y.–(BUSINESS WIRE)– Second paragraph, first sentence of release should read: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated Plastic Scintillating Detector (PSD) sensors used during cancer treatments to measure photon and electron radiation therapy as an adjunct to …

Plus »

Quanterix Appoints Amol Chaubal as Chief Financial Officer

Thursday, March 28th 2019 at 8:00pm UTC Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth LEXINGTON, Mass.–(BUSINESS WIRE)– Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has …

Plus »

Cytonus Therapeutics Announces Poster Presentation at the 2019 American Association for Cancer Research Annual Meeting

Thursday, March 28th 2019 at 8:04pm UTC SAN DIEGO–(BUSINESS WIRE)– Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be presenting preclinical data for its Cargocyte™ technology platform at the American Association for Cancer Research (AACR) annual meeting March 29 – April …

Plus »

OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy

Thursday, March 28th 2019 at 8:01pm UTC LATHAM, N.Y.–(BUSINESS WIRE)– AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration (FDA) granted an expanded 510(k) clearance for the OARtrac …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.